We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

45 hedge funds and large institutions have $141M invested in Protalix BioTherapeutics in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

0.11% more ownership

Funds ownership: 3.75% → 3.87% (+0.11%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 47 → 45 (-2)

12% less capital invested

Capital invested by funds: $159M → $141M (-$18.4M)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

98% less call options, than puts

Call options by funds: $40K | Put options by funds: $2.2M

Holders
45
Holders Change
-2
Holders Change %
-4.26%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
8
Increased
14
Reduced
9
Closed
10
Calls
$40K
Puts
$2.2M
Net Calls
-$2.16M
Net Calls Change
+$1.47M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$2.53M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$1.6M
3
BlackRock
BlackRock
New York
+$1.55M
4
CCM
Camber Capital Management
Massachusetts
+$884K
5
First Eagle Investment Management
First Eagle Investment Management
New York
+$842K

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$1.55M
2
SAM
Silverback Asset Management
North Carolina
-$1.23M
3
U
UBS
Switzerland
-$991K
4
Federated Hermes
Federated Hermes
Pennsylvania
-$851K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$600K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$129K -$52K -1,235 -27%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$123K -$118K -2,791 -47%
OC
28
Oppenheimer & Co
New York
$120K +$130K +3,085 New
CCA
29
Catalyst Capital Advisors
New York
$117K – – –
Goldman Sachs
30
Goldman Sachs
New York
$112K -$134K -3,172 -52%
TC
31
TFS Capital
Pennsylvania
$106K +$115K +2,730 New
CL
32
CSS LLC
Illinois
$94K +$101K +2,410 New
HCM
33
Highbridge Capital Management
New York
$89K +$96.7K +2,296 New
ARTA
34
A.R.T. Advisors
New York
$82K -$16.2K -384 -15%
Citadel Advisors
35
Citadel Advisors
Florida
$79K +$79.6K +1,890 +1,313%
Jane Street
36
Jane Street
New York
$42K +$45.2K +1,073 New
Bank of America
37
Bank of America
North Carolina
$28K +$16.8K +400 +120%
U
38
UBS
Switzerland
$21K -$991K -23,533 -98%
Citigroup
39
Citigroup
New York
$10K – – –
Morgan Stanley
40
Morgan Stanley
New York
$10K +$11.2K +267 New
TRCT
41
Tower Research Capital (TRC)
New York
$7K +$1.47K +35 +22%
DIA
42
Denver Investment Advisors
Colorado
$81 – – –
SAM
43
Silverback Asset Management
North Carolina
– -$1.23M -27,220 Closed
ERSOT
44
Employees Retirement System of Texas
Texas
– -$412K -9,100 Closed
OAM
45
Oberweis Asset Management
Illinois
– -$246K -5,420 Closed
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$235K -5,050 Closed
FMBTD
47
First Midwest Bank Trust Division
Illinois
– -$169K -3,723 Closed
Millennium Management
48
Millennium Management
New York
– -$156K -3,439 Closed
Nomura Holdings
49
Nomura Holdings
Japan
– -$109K -2,370 Closed
VanEck Associates
50
VanEck Associates
New York
– -$97K -2,149 Closed
1
2
3

PLX Hedge Fund Activity: Q4 2013 in Review

45 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2013, worth a combined $141M — down 12% from $159M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of PLX and 8 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 14 added.

The largest buyer was Great Point Partners, adding an estimated $2.53M. The largest seller was BlackRock Advisors, cutting an estimated $1.55M.

  • 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2013, down from 47 in Q3 2013.
  • Funds reported $141M of Protalix BioTherapeutics stock for Q4 2013, down 12% quarter-over-quarter.
  • 8 funds opened new Protalix BioTherapeutics positions in Q4 2013 and 10 closed out, a net change of -2 holders.
  • The largest Protalix BioTherapeutics buyer in Q4 2013 was Great Point Partners, an estimated $2.53M added.
  • The largest Protalix BioTherapeutics seller in Q4 2013 was BlackRock Advisors, an estimated $1.55M sold.

Based on aggregated 13F filings for Q4 2013.